Table 1.

Patient characteristics

Patient	Age (yrs)	Primary or Recurrent	Metastatic site	Histologya	ER/PR/HER-2a	Ki-67a	Gradea
1	59	Recurrent	Bone, lymph node, other	Ductal	+/−/+	NA	III
2	47	Recurrent	Bone, lymph node	Ductal	+/+/−	10	I
3	40	Recurrent	Lung, liver, lymph node	Ductal	+/+/−	5	II
4	27	Primary	Lung, lymph node	Ductal	+/+/−	10	II
5	52	Recurrent	Bone, lymph node	Ductal	+/−/−	NA	NA
6	50	Recurrent	Bone, liver	Ductal	+/−/+	NA	II
7	54	Recurrent	Lung, lymph node	Ductal	−/−/−	NA	NA
8	62	Recurrent	Bone, other	Ductal	−/−/−	30	III
9	37	Recurrent	Bone	Ductal	+/+/−	40	II
10	48	Recurrent	Bone	Ductal	+/+/−	NA	II
11	67	Primary	Bone	NST	+/+/−	10	I
12	43	Recurrent	Bone	Ductal	−/−/−	NA	III
13	55	Recurrent	Lymph node	NST	+/+/+	NA	NA
14	38	Recurrent	Bone, lung, liver	Ductal	+/+/−	NA	N A
15	61	Primary	Bone, lung	NST	+/+/−	30	II
16	59	Recurrent	Bone	Ductal	+/−/−	10	III
17	52	Recurrent	Bone	Ductal	+/+/+	NA	NA
18	37	Recurrent	Bone, lung, liver, other	NST	+/+/+	50	III
19	50	Recurrent	Bone	Ductal	+/−/−	NA	NA
20	59	Recurrent	Other	Ductal	−/−/−	30	III
21	55	Recurrent	Bone, lung, liver	Ductal	−/−/−	20	II
22	57	Recurrent	Lymph node, other	NST	−/−/−	40	III
23	45	Recurrent	Other	NST	+/+/−	15	NA
24	51	Recurrent	Lung, liver	Ductal	+/+/+	20	II
25	54	Recurrent	Other	NST	−/−/−	> 90	III

^a Acquired at diagnosis

Abbreviations: ER estrogen receptor, PR progesterone receptor, HER-2 human epidermal growth factor receptor 2, NA not available, NST no special type